These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 28900511)

  • 1. A Nanosystem of Amphiphilic Oligopeptide-Drug Conjugate Actualizing Both αvβ3 Targeting and Reduction-Triggered Release for Maytansinoid.
    Liang Y; Li S; Wang X; He B; He B; Dai W; Zhang H; Wang X; Wang Y; Zhou D; Zhang Q
    Theranostics; 2017; 7(13):3306-3318. PubMed ID: 28900511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of the antitumor efficacy of peptide-doxorubicin conjugates with different linkers.
    Liang Y; Li S; Wang X; Zhang Y; Sun Y; Wang Y; Wang X; He B; Dai W; Zhang H; Wang X; Zhang Q
    J Control Release; 2018 Apr; 275():129-141. PubMed ID: 29408580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. α
    Zhong P; Meng H; Qiu J; Zhang J; Sun H; Cheng R; Zhong Z
    J Control Release; 2017 Aug; 259():176-186. PubMed ID: 27986551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Smart Nano-Prodrug Platform with Reactive Drug Loading, Superb Stability, and Fast Responsive Drug Release for Targeted Cancer Therapy.
    Meng H; Zou Y; Zhong P; Meng F; Zhang J; Cheng R; Zhong Z
    Macromol Biosci; 2017 Oct; 17(10):. PubMed ID: 28464449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Redox-sensitive carrier-free nanoparticles self-assembled by disulfide-linked paclitaxel-tetramethylpyrazine conjugate for combination cancer chemotherapy.
    Zou L; Liu X; Li J; Li W; Zhang L; Fu C; Zhang J; Gu Z
    Theranostics; 2021; 11(9):4171-4186. PubMed ID: 33754055
    [No Abstract]   [Full Text] [Related]  

  • 6. Peptide-Drug Conjugate-Based Nanocombination Actualizes Breast Cancer Treatment by Maytansinoid and Photothermia with the Assistance of Fluorescent and Photoacoustic Images.
    Sun Y; Liang Y; Dai W; He B; Zhang H; Wang X; Wang J; Huang S; Zhang Q
    Nano Lett; 2019 May; 19(5):3229-3237. PubMed ID: 30957499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. α
    Zhong P; Gu X; Cheng R; Deng C; Meng F; Zhong Z
    Int J Nanomedicine; 2017; 12():7913-7921. PubMed ID: 29138558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pH-responsive cell-penetrating peptide-modified liposomes with active recognizing of integrin αvβ3 for the treatment of melanoma.
    Shi K; Li J; Cao Z; Yang P; Qiu Y; Yang B; Wang Y; Long Y; Liu Y; Zhang Q; Qian J; Zhang Z; Gao H; He Q
    J Control Release; 2015 Nov; 217():138-50. PubMed ID: 26368312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
    Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R
    Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting efficiency of RGD-modified nanocarriers with different ligand intervals in response to integrin αvβ3 clustering.
    Guo Z; He B; Jin H; Zhang H; Dai W; Zhang L; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
    Biomaterials; 2014 Jul; 35(23):6106-17. PubMed ID: 24794924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction Responsive Self-Assembled Nanoparticles Based on Disulfide-Linked Drug-Drug Conjugate with High Drug Loading and Antitumor Efficacy.
    Song Q; Wang X; Wang Y; Liang Y; Zhou Y; Song X; He B; Zhang H; Dai W; Wang X; Zhang Q
    Mol Pharm; 2016 Jan; 13(1):190-201. PubMed ID: 26629710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic active targeting of dually integrin αvβ3/CD44-targeted nanoparticles to B16F10 tumors located at different sites of mouse bodies.
    Shi S; Zhou M; Li X; Hu M; Li C; Li M; Sheng F; Li Z; Wu G; Luo M; Cui H; Li Z; Fu R; Xiang M; Xu J; Zhang Q; Lu L
    J Control Release; 2016 Aug; 235():1-13. PubMed ID: 27235150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revival of a potent therapeutic maytansinoid agent using a strategy that combines covalent drug conjugation with sequential nanoparticle assembly.
    Xie K; Song S; Zhou L; Wan J; Qiao Y; Wang M; Xie H; Zhou L; Zheng S; Wang H
    Int J Pharm; 2019 Feb; 556():159-171. PubMed ID: 30553007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of RGD peptidomimetic-paclitaxel conjugates bearing lysosomally cleavable linkers.
    Dal Corso A; Caruso M; Belvisi L; Arosio D; Piarulli U; Albanese C; Gasparri F; Marsiglio A; Sola F; Troiani S; Valsasina B; Pignataro L; Donati D; Gennari C
    Chemistry; 2015 Apr; 21(18):6921-9. PubMed ID: 25784522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation of arginine-glycine-aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization.
    Chang CY; Wang MC; Miyagawa T; Chen ZY; Lin FH; Chen KH; Liu GS; Tseng CL
    Int J Nanomedicine; 2017; 12():279-294. PubMed ID: 28115846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Redox-responsive amphiphilic camptothecin prodrug nanoparticles for targeted liver tumor therapy.
    Lu L; Li B; Lin C; Li K; Liu G; Xia Z; Luo Z; Cai K
    J Mater Chem B; 2020 May; 8(17):3918-3928. PubMed ID: 32227058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of integrin α
    Lv X; Zhang C; Shuaizhen Q; Yu R; Zheng Y
    Biomed Pharmacother; 2020 Aug; 128():110236. PubMed ID: 32447209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.
    Erickson HK; Park PU; Widdison WC; Kovtun YV; Garrett LM; Hoffman K; Lutz RJ; Goldmacher VS; Blättler WA
    Cancer Res; 2006 Apr; 66(8):4426-33. PubMed ID: 16618769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modification of the C16Y peptide on nanoparticles is an effective approach to target endothelial and cancer cells via the integrin receptor.
    Hamano N; Negishi Y; Fujisawa A; Manandhar M; Sato H; Katagiri F; Nomizu M; Aramaki Y
    Int J Pharm; 2012 May; 428(1-2):114-7. PubMed ID: 22421321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.